Teva Pharmaceutical Industries (TEVA) Buildings (2009 - 2025)

Teva Pharmaceutical Industries (TEVA) has reported Buildings for 17 consecutive years, with $2.3 billion the latest figure, recorded in Q4 2025.

• Quarterly Buildings rose 18.24% year-over-year to $2.3 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.3 billion (up 18.24% YoY) and the FY2025 annual result came in at $2.3 billion, up 18.24% from the prior year.
• Buildings climbed to $2.3 billion in Q4 2025 per TEVA's latest filing, from $2.0 billion in the prior quarter.
• Over the last five years, Buildings for TEVA reached as high as $2.6 billion in Q4 2021 and fell as low as $2.0 billion in Q4 2024.
• A 5-year average of $2.4 billion and a median of $2.5 billion in 2022 frame the typical range for Buildings.
• Annual changes were most pronounced in 2024 — Buildings slipped 20.9% — and 2025, when it increased 18.24%.
• Year by year, Buildings stood at $2.6 billion in 2021, then retreated by 4.09% to $2.5 billion in 2022, then advanced by 1.02% to $2.5 billion in 2023, then retreated by 20.9% to $2.0 billion in 2024, then increased by 18.24% to $2.3 billion in 2025.
• According to Business Quant data, Buildings over the past three periods registered $2.3 billion, $2.0 billion, and $2.5 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.